3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
7
Other hematologic neoplasm
5
CNS
5
Tumor-Agnostic
4
Sarcoma
4
Other solid neoplasm
4
Lymphoid
4
Head & Neck
4
Genitourinary
4
Gastrointestinal
4
Dermatologic
4
Breast
4
Endocrine
3
Gynecologic
2
Plasma cell
1
NET
1
Myeloid
1
Classical hematology
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
lutetium Lu 177 dotatate
41
Everolimus
38
Magnetic Resonance Spectroscopy
18
Temozolomide
17
lanreotide
16
gallium Ga 68 dotatate
15
Octreotide
14
pembrolizumab
13
Nivolumab
13
Capecitabine
12
cabozantinib
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
11
surufatinib
9
pasireotide
9
Sunitinib
9
Specimen Handling
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Lutetium-177
8
Carboplatin
8
amino-acid, glucose, and electrolyte solution
6
Ipilimumab
6
Ga(III)-DOTATOC
6
Fluorodeoxyglucose F18
6
Etoposide
6
Cisplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
copper dotatate CU-64
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
entrectinib
×
NET
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA